pharmaphorum January 13, 2025
Biogen has offered to buy all the shares in Sage Therapeutics that it doesn’t already own, taking control of their novel antidepressant Zurzuvae.
The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company’s share price on Friday and is estimated by Reuters to be worth around $442 million. Biogen has a longstanding alliance in place with Sage and co-markets Zurzuvae (zuranolone), which is FDA-approved for post-partum depression (PPD).
The offer comes during a period of weakness for Sage, whose shares have plummeted almost 80% in the last year after a series of setbacks in 2024 that kicked off with a narrower-than-hoped FDA approval last year for Zurzuvae in PPD, but not the larger indication of major...
Today's Sponsors
Today's Sponsor